CLX

Business Profile & Competitive Position

The Clorox Company operates in the Consumer Defensive sector under the Household & Personal Products industry. Its portfolio spans bleach and cleaning products through the Clorox, Pine-Sol, CloroxPro, and Clorox Healthcare brands; waste bags and wraps through Glad; grilling products through Kingsford; food and dressings through Hidden Valley; water filtration through Brita; natural personal care through Burt’s Bees; and cat litter through Fresh Step. After the April 2026 acquisition of GOJO Industries, Purell joins the portfolio, deepening Clorox’s health-and-hygiene positioning and adding a larger business-to-business channel. The company generated fiscal 2026 net sales of $6.7 billion, employs roughly 9,200 people, sells in about 95 markets, and maintains operations in approximately 25 countries.

On a strict profitability basis, Clorox earns an 8.7% net margin. That is a mid-tier margin for branded household products: high enough to suggest pricing power and stable recurring demand, but not so wide that it signals deep luxury-level pricing. The return on equity (ROE) is reported at -1,893.5%, which on its face looks alarming, but in Clorox’s case it is almost certainly an accounting artifact rather than an operational collapse. A very high negative ROE usually means shareholders’ equity has been pushed deeply negative, frequently through years of share repurchases, accumulated treasury stock, or debt-funded buybacks. With positive net margin and a still-large consumer-franchise footprint, the figure tells us more about the leverage and capital-structure choices embedded in the balance sheet than about whether the core business is profitable.

Financial Posture

Clorox currently carries a $10.5 billion market cap and trades at a P/E ratio of 18.0. For a large, slow-growth consumer-staples name, a high-teens multiple sits in the middle of the historical range for the sector: not screaming value, but not priced for heroism either. The multiple implies the market expects low- to mid-single-digit earnings growth supported by pricing power, cost discipline, and eventually the GOJO integration, rather than a rapid acceleration in sales.

The company’s beta of 0.57 is consistent with the defensive label. The stock has been less volatile than the broad market, which is typical for companies whose products move off shelves in relatively steady volumes regardless of the economic cycle. Investors often look at such profiles as relative havens during broader market drawdowns, though that same defensiveness can mean muted participation in rallies.

The key balance-sheet story is that outsized negative ROE. Because Clorox remains profitable on an operating basis, the negative equity is a reason to look past headline ROE and instead scrutinize debt levels, buyback intensity, and free-cash-flow generation directly. In other words, the financial posture is that of a cash-generative staples operator whose capital return program has significantly altered the equity base.

Strategic Priorities & Outlook

Clorox’s most recent 10-K filing lays out a near-term agenda centered on its IGNITE strategy, which has four stated pillars: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio. These are not vague aspirations; they translate into concrete operational priorities over the next few quarters.

First, the company is pushing to complete and optimize a new enterprise resource planning (ERP) system and a broader digital transformation. The goal is to generate long-term efficiencies across supply chain, digital commerce, innovation, and brand building. Fiscal 2026 already showed how disruptive that transition can be: organic sales and earnings declined, and diluted EPS fell 26%, partly because some sales had been pulled forward into fiscal 2025 as the company prepared for the ERP rollout. That timing effect suggests near-term comparisons may remain noisy even as the system stabilizes.

Second, Clorox is directing capital toward strong brands, strategic digital capabilities, and a streamlined operating model, with the aim of building a more resilient company capable of consistent, profitable growth. Third, the April 2026 GOJO acquisition is meant to advance health-and-hygiene expansion and portfolio optimization, particularly in professional and institutional markets. This is a deliberate pivot toward the B2B channel and away from near-total dependence on retail consumers.

One of the more specific risk factors the filing discloses is customer concentration. Walmart alone accounted for 26% of fiscal 2026 consolidated net sales, and the five largest customers represented about half of consolidated net sales. That concentration means pricing negotiations, shelf resets, and inventory changes at a single large retailer can have an outsized impact on quarterly results. The 10-K also notes that the Glad bags and wraps venture with Procter & Gamble expired on January 31, 2026, requiring Clorox to purchase P&G’s 20% interest; Glad retained core intellectual-property licenses on a royalty-free basis. That removes partnership complexity but also means Clorox now fully owns the economics and must fund future growth in the category itself.

Macro & Geopolitical Exposure

As a Household & Personal Products company, Clorox is exposed to several macro themes that apply to the industry broadly rather than to Clorox alone. The first is commodity input costs. Cleaning products, packaging, and pet litter rely on resins, chemicals, pulp, paperboard, and energy. Volatility in oil prices, petrochemical markets, and natural-gas costs can swing gross margins when hedging coverage rolls off.

Second, currency risk matters because Clorox sells in about 95 markets. A stronger U.S. dollar reduces the dollar value of overseas revenue and can pressure reported results even when local-currency demand is stable.

Third, supply-chain and logistics exposure remains relevant. ERP transitions, port congestion, trucking costs, and labor availability can affect the ability to keep shelves stocked and promotional calendars on track.

Fourth, consumer staples often face regulatory attention around ingredient safety, labeling, environmental packaging, and recycling mandates. While not company-specific, shifts in Environmental Protection Agency rules, state plastic regulations, or chemical disclosure requirements can force formula changes, packaging redesign, or compliance spending across the industry.

Finally, trade policy can affect both raw-material sourcing and finished-goods sales, particularly for companies with manufacturing footprints spanning multiple countries. Tariffs on chemicals, resins, or imported components can squeeze margins if price increases cannot be fully passed through.

Recent Developments

Recent headlines have centered on earnings expectations and dividend-paying staples, reflecting a market reassessment of income stocks. On October 26, 2026, zacks.com published “Clorox (CLX) Earnings Expected to Grow: Should You Buy?,” framing the upcoming November 2 report against the question of whether earnings momentum can support the stock. On October 25, 2026, 247wallst.com ran “Whirlpool’s Dividend Collapse Is a Warning for These 3 High-Yield Stocks,” using a dividend cut elsewhere as a prompt for investors to stress-test payout durability across household names. On October 24, 2026, fool.com highlighted “5 Top Dividend Stocks Yielding 5% or More to Buy Right Now for Passive Income,” placing Clorox in the dividend-income conversation. And on October 23, 2026, seekingalpha.com published “Dividend Champion, Contender, And Challenger Highlights: Week October 25,” continuing the theme of yield-focused screeners.

Together, these headlines suggest the market is treating Clorox as a yield-sensitive defensive play heading into the next earnings release rather than as a growth re-rating candidate. That tone is important context for how the stock may behave if the upcoming report reinforces the current earnings trajectory.

Earnings Behavior & Post-Earnings Drift

Clorox has beaten earnings estimates in 6 of the last 8 quarters, for a 75% beat rate. The average earnings surprise across those eight quarters is 9.6%, which is meaningful for a low-beta staples name. Despite that track record, the price reaction has not always followed the headline beat-or-miss binary in an obvious way.

Looking at the most recent quarter, reported August 3, 2026, Clorox delivered actual EPS of $1.66 versus an estimate of $1.64, a 1.2% surprise. The stock rose 6.52% the next day and extended gains to 9.61% over the following five sessions. That episode shows how a modest beat can be amplified when the market is hungry for confirmation that operational headwinds are fading.

The prior quarter, reported April 30, 2026, brought a larger earnings beat: $1.64 actual versus $1.55 estimated, a 5.8% surprise. Yet the stock fell 9.67% the next day and was down 4.49% over the next five sessions. That divergence is a clear reminder that bottom-line results are only one input; guidance, gross-margin trajectory, and top-line trends can easily overwhelm a positive EPS print.

The February 3, 2026 quarter was a miss: actual EPS $1.39 versus estimate $1.43, a -2.8% surprise. Counterintuitively, shares rose 2.43% the next day and 5.63% over the next five sessions, suggesting the market had priced in worse news or that forward guidance improved the narrative. The quarter before that, reported November 3, 2025, saw a $0.85 actual EPS versus $0.818 estimate, a 3.9% beat, but the stock managed only 1.17% the next day and then drifted -4.08% over five sessions.

Averaging across the last eight quarters, the five-trading-day drift after earnings is +1.67%, classified as an “up” drift. The next report is scheduled for November 2, 2026, after the market close, with a consensus EPS estimate of $1.07. The data show that beating estimates has been the norm, but the post-release price path has been far from predictable on a quarter-by-quarter basis.

For a deeper dive into how institutional analysts are sizing up Clorox ahead of the November 2 report, including updated model assumptions, margin drivers, and the full institutional verdict, consult the platform’s complete earnings intelligence dashboard.